http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
CYP2C19 Polymorphism in Korean Patients on Warfarin Therapy
Sukhyang Lee,Hyun Jin Hwang,Jae-Moon Kim,Chin-Sang Chung,Jeong Hee Kim 대한약학회 2007 Archives of Pharmacal Research Vol.30 No.3
This study was designed to assess the effect of CYP2C19 polymorphism on warfarin dosage requirements and bleeding complications in the Korean population. Patients were placed into one of four groups according to the dose of warfarin they received and the presence of bleeding complications: regular dose control, regular dose bleeding, low dose control, and low dose bleeding. Genotyping for CYP2C19*2 and CYP2C19*3 was performed by the restriction fragment length polymorphism method for each patient and each study group. The measured internal normalized ratio (INR) in each dose group was similar even though the administered dosage was significantly different. A total of 66 patients were evaluated for CYP2C19 polymorphism. Among them 25 patients (37.9%) were homozygous wild type. Four patients (6.1%) had heterozygous mutations at both loci. Others had mutations on either the CYP2C19*2 or *3 locus. Higher genetic variation was observed in CYP2C19*2 than in CYP2C19*3 among Korean patients on warfarin therapy. Our data suggested that there is a higher incidence of bleeding complications in patients who have a higher allele frequency of CYP2C19. It was also revealed that the distribution of CYP2C19 polymorphism among Asian populations is more similar than of the distribution among Caucasian populations.
Cilostazol이 제2형 당뇨병 환자의 심혈관 합병증과 혈청지질에 미치는 영향
이영숙,이영미,김광원,최경업,이숙향 한국병원약사회 2002 병원약사회지 Vol.19 No.4
PURPOSE: Cliostazol, a phosphodiesterase Ⅲ inhibitor, is an antiplatelet agent for treatment of ischemic symptoms of peripheral vascular disease in the diabetes. In addition, it has been claimed to have beneficial effect on plasma lipid level. The objective of this study was to evaluate retrospectively the effect of cilostazol administration on cardiovascular events and serum lipid levels in patients with type 2 diabetes mellitus (DM). METHODS: DM patients on cilostazol for longer than 6 months were evaluated from September, 1996 to June, 2000 for lipid profile, HbA1c, postprandial glucose, urinary albumin excretion, cardiovascular events. Dosage of cilostazol was 100㎎/day with range of 50-200㎎/day. Primary outcome variable was any cardiovascular events during treatment and secondary variables were changes in lipid level, urinary albumin excretion and adverse events. Lipid level was compared between the groups with or without lipid lowering agents. Patients were evaluated for bleeding events in combination with other antiplatelet agents, such as aspirin, ticlopidine and warfarin. RESULTS: Total 180 patients were included Mean age was 60.8±9.9 years; number of male patient, 90(50%); DM duration, 12.4±8.1 years; family history of DM, 61(33.9%); family history of cardiovascular events, 15(8.3%) and smoking, 32(17.8%). The cardiovascular events were noted in 8 cases out of 180 (4.4%). Systolic blood pressure and age were risk factors in correlation with cardiovascular events. During treatment with cilostazol, there were no significant changes in blood glucose. Among 19 patients with serum lipid profile before and after cilostazol treatment, there were no significant changes in serum lipid levels with LDL-cholesterol reduced form 130.8±30.3 ㎎/㎗ at baseline to 120.0±43.1 at 1 yr and 125.4±27.3 at 3 yr (p=0.052). Bleeding event was in 1 case of co-administration with other antiplatelet agents that were aspirin (87), ticlopidene(7), warfarin(2) CONCLUSION: Cilostazol has been used for peripheral vascular disease in DM patients with antiplatelet activity and lipid lowering effect in part. Small effect on lipid level can be expected by itself or in combination with other lipid lowering agents and the cardiovascular can be prevented in patients with type 2 DM.
Lee, Jimin,Noh, Yoojin,Shin, Sooyoung,Lim, Hong-Seok,Park, Rae Woong,Bae, Soo Kyung,Oh, Euichaul,Kim, Grace Juyun,Kim, Ju Han,Lee, Sukhyang Dove Medical Press 2016 THERAPEUTICS AND CLINICAL RISK MANAGEMENT Vol.12 No.-
<P>Statin therapy is beneficial in reducing cardiovascular events and mortalities in patients with atherosclerotic cardiovascular diseases. Yet, there have been concerns of increased risk of diabetes with statin use. This study was aimed to evaluate the association between statins and new onset diabetes mellitus (NODM) in patients with ischemic heart disease (IHD) utilizing the Korean Health Insurance Review and Assessment Service claims database. Among adult patients with preexisting IHD, new statin users and matched nonstatin users were identified on a 1:1 ratio using proportionate stratified random sampling by sex and age. They were subsequently propensity score matched further with age and comorbidities to reduce the selection bias. Overall incidence rates, cumulative rates and hazard ratios (HRs) between statin use and occurrence of NODM were estimated. The subgroup analyses were performed according to sex, age groups, and the individual agents and intensities of statins. A total of 156,360 patients (94,370 in the statin users and 61,990 in the nonstatin users) were included in the analysis. The incidence rates of NODM were 7.8% and 4.8% in the statin users and nonstatin users, respectively. The risk of NODM was higher among statin users (crude HR 2.01, 95% confidence interval [CI] 1.93–2.10; adjusted HR 1.84, 95% CI 1.63–2.09). Pravastatin had the lowest risk (adjusted HR 1.54, 95% CI 1.32–1.81) while those who were exposed to more than one statin were at the highest risk of NODM (adjusted HR 2.17, 95% CI 1.93–2.37). It has been concluded that all statins are associated with the risk of NODM in patients with IHD, and it is believed that our study would contribute to a better understanding of statin and NODM association by analyzing statin use in the real-world setting. Periodic screening and monitoring for diabetes are warranted during prolonged statin therapy in patients with IHD.</P>
이인향(Iyn-Hyang Lee),이형원(Hyung Won Lee),제남경(Nam Kyung Je),이숙향(Sukhyang Lee) 대한약학회 2012 약학회지 Vol.56 No.5
A product labelling is one of key tools in ensuring that a patient uses drugs safely and effectively in self-care without professional support. This study aimed to explore the readability and comprehensibility of the information contained on two package inserts of medicines. Two package inserts were tested with first year college students. Fifty-one potential consumers underlined words they could not understand and answered 10 scenario questions. Any differences among groups with different characteristics were statistically tested. Secondly, the readability of two package inserts was assessed with comparison to the level of the 6th grade Korean textbooks. As results, more than 80% of participants properly replied to straightforward questions concerning indication, dosage, duplication, use in pregnancy and contraindication, and 73% about formulation. Less than half answered correctly in multiple choice questions about pediatric use (41%) and side effects (35%). Little discrepancy was observed in the comprehensibility between participants' characteristics. Drug inserts contained about 20% more professional-level words than 6th grade textbooks. In conclusion, Korean consumers may face challenges to understand drug information due to professional terminology and outdated expressions in the current package inserts. To secure safe and effective use of over-the-counter agents, greater efforts should be made to develop more consumer friendly labels. In the other hand, educational supports are required to prepare consumers in a proper level of knowledge for the safe use of drugs.
이인향 ( Iyn Hyang Lee ),계승희 ( Seunghee Kye ),이숙향 ( Sukhyang Lee ) 영남대학교 약품개발연구소 2014 영남대학교 약품개발연구소 연구업적집 Vol.24 No.0
Purpose: This study aims to investigate consumers` demand of and perspective on drug information domestically availableand uncover hurdles that they faced while utilizing information. Methods: We conducted a survey of 101 consumers,face-to-face after obtaining informed consent. Chi-squared, or Fisher`s exact tests, and multivariate logistic modelswere used to investigate the association between participants` perceptions and characteristics. Results: As results, participantsshowed the highest demand for “Adverse effects >90%”; “Drug interactions/Dosage/Drug-food interactions/ Indication>80%”, and utilized package inserts (52%), doctors (41%) and pharmacists (36%) most often as informationsources. Generally, the most common difficulty consumers suffered with was that “it is hard to understand (51%)”. With public sources of drug information, sixty one percent of participants were “unaware of the provision of information”,resulting in strikingly low usage rates (5~11%). Subgroup analyses indicated that the older (≥ 50 years) and thedisadvantaged might have been placed in the blind spot of information mostly developed online (p<0.05).Conclusion:In conclusion, public sources of drug information that have been developed online might fail to meet consumers`demand. Greater efforts should be made to balance the development of the information sources between online andoffline, and to increase accessibility of the established information sources.